PPHM Peregrine Pharmaceuticals Inc. PPHM Stock Message Board

PPHM Peregrine Pharmaceuticals Inc. PPHM Stock Message Board

http://investorshangout.com/board/55152/Pereg...s-Inc-PPHM

trial
data
pphm
peregrine
cancer
nsclc
mos
bavi
new
hellip
article
potential
patients
bavituximab
trials
clinical
phase
fda
ceo
cotara
very
avid
steve
were
tumor
imaging
which
news
antips
see
results
pstargeting
ndline
antibodies
thorpe
about
into
talk
therapy
conf
immune
survival
its
could
approval
protocol
most
goal
pgm
call
arm
think
pgn
weve
would
more
partnering
arms
these
phb
still
mabs
comp
antibody
presents
presented
treatment
seen
than
transcript
like
also
they
regulatory
ist
antiviral
dose
lot
init
meeting
drug
iii
qtly
philip
study
pphms
affitech
hellipdr
garnick
going
randomized
mrpatinmn
joins
great
mosmos
future
platform
cotarabrain
research
min
grant
bull
using
product
asco
king
enrollment
biopharm
aacr
part
kings
peregrines
over
mab
review
program
treatments
studies
drugs
cancers
orr
ongoing
httpclinicaltrialsgovctshownct
added
out
cotaragbm
stock
case
need
completed
potentially
time
support
pts
partners
profile
major
some
hellipsk
brain
annual
utsw
forward
eop
update
sites
since
tumors
vaccine
pancreatic
var
partner
bavis
httptinyurlcomyrwqm
fullyhuman
binding
ftms
years
options
httpperegrinetrialscom
brekken
inc
therapeutics
therapeutic
favorable
other
working
human
pharmaceuticals
company
posters
poster
cmo
healthcare
preclin
hiv
hide
viruses
such
completely
after
agent
contract
qtlycc
patient
symposium
strategy
against
gbm
phil
based
ups
approach
interested
today
buy
activity
initiated
moving
interest
expect
discussions
srb
efficacy
effects
evaluate
evaluating
both
roth
excerpts
dev
moa
initiate
registrational
accelerated
bioservices
board
really
well
things
info
deal
thorpes
thru
exposed
believe
reached
side
cells
robert
responses
securities
been
broad
breast
registration
broadspectrum
rob
public
china
quote
cfo
range
remarkable
semper
boards
showed
represents
between
actively
said
showing
business
resp
response
nyc
investigatorsponsored
join
just
interview
interim
infections
innate
justmarried
end
liver
longer
looking
live
dukepphm
licensing
line
infection
indication
hard
httptinyurlcomnkwrml
global
hcv
hellipsking
httptinyurlcomcsspbz
highly
fyq
function
importantly
india
feel
fever
full
frontline
door
diseases
patent
path
pdf
past
partnership
cprit
parties
phiii
confident
present
prior
complete
plan
pipeline
placebo
opportunity
openlabel
diagnostic
diag
much
different
mid
disease
mgkg
design
next
sking
oncology
number
david
note
novel
process
pathway
addl
specifically
unmet
bavidoce
thats
updates
those
specific
advanced
top
applications
tnt
area
viral
status
vhf
stocks
agreement
sufficient
agency
alan
basis
tarvacin
technologies
webcast
used
take
topline
unique
because
vta
administered
slides
treated
trend
control
fhbavi
level
corp
imagine
far
usa
less
work
continuing
continue
consider
pharmaceutical
links
system
dukes
fight
ibcs
considered
consideration
targeted
immunology
coverage
ind
world
parseghian
including
facility
own
incl
oxford
tested
duke
participate
outcome
final
treating
targets
immunotherapy
cotaragmb
cotaras
ask
fact
included
piper
avoid
prepare
httptinyurlcomwrrso
combinations
back
funding
preclinical
fund
commodities
commercial
sues
previous
price
progressplans
project
george
promising
progress
programs
collaboration
collab
generate
studying
weeks
agreed
planned
ebola
trends
plasma
eager
forex
lnsclc
pivotal
conduct
follow
supplies
plos
post
likely
fulltime
valuable
compared
compelling
compound
point
points
fourth
findings
ourselves
lung
job
diff
didnt
warrants
appointed
mlv
discussed
discrepancies
lawsuit
minyanville
announced
even
determine
april
detail
desire
msg
developing
size
approved
absolutely
mouse
discusses
mfg
documents
kinggarnickshanlytle
medical
enrolled
kingshangarnicklytle
dont
many
doses
matter
majority
medipharm
docetaxel
tools
app
drthorpe
esp
merckkgaas
envelope
launches
doce
entire
kenneth
nabtt
exceeded
look
innovative
one
proposing
only
experience
expected
interesting
thirdparty
andrew
danapt
lead
inhibitory
orrher
long
extraordinary
extremely
updated
csa
optical
therapies
expression
upd
under
ntsplus
either
exciting
ipgn
niaid
near
ukraine
above
nature
ndash
describe
exp
dec
day
internetforumuser
animal
loss
low
days
nor
expands
unblinded
lowdose
last
supply
cash
scpt
steps
rectal
videos
secret
httptinyurlcommh
biosimilars
ref
history
step
advancing
candidates
hellipceo
httptinyurlcomlmws
historical
his
refractory
adam
secured
set
services
bind
biggest
affitechs
several
bhaynes
bidrite
rat
sept
basically
certainly
activities
chamow
soc
rates
host
stats
blocks
space
sparked
responsestatus
httptinyurlcomkhopad
prostate
spa
help
rothocdanapt
role
httptinyurlcomfpgngu
rhuph
right
ringmaster
revs
httptinyurlcomhedbaf
build
bavimg
rsquo
starting
high
sorafenib
remain
baviav
httptinyurlcomkyas
cancerfighting
while
release
remaining
stated
httptinyurlcomkquve
russiacis
boston
report
her
herpes
repga
checkpoint
solid
show
class
httptinyurlcompjcbw
clearly
strength
raises
cjgaddy
quality
group
shm
story
vessels
bavituximabs
govt
vegfrgel
slide
given
before
site
provides
clinicaltrialsgov
whose
googletagdisplaydivgptad
being
significant
signs
quite
qevents
halflife
shareholders
radiation
httpclinicaltrialsgovshownct
shares
httptinyurlcombfjmva
httptinyurlcomanmaa
hepatitis
administration
hepc
anticipating
expanding
httptinyurlcomaulds
antipe
hemorrhagic
httptinyurlcomapro
enhances
examples
efficacious
eward
advance
evolution
adopted
advantage
httptinyurlcomagwno
httptinyurlcomamwyj
herceptin
endorsement
httptinyurlcomamxjw
examgen
exactly
expand
effect
exercise
exgenentech
httptinyurlcomaynyb
animals
hellipwe
existing
hellipvirus
hellipsteve
engaged
enhance
hellipto
eastern
execute
httptinyurlcomawg
httptinyurlcomavred
excerptsslides
evilevitch
anionic
eng
engage
excited
exec
execs
excluded
excl
educational
antipsg
hsv
elim
estate
elparentnodeinsertbefores
hivvaccine
establishing
holds
emps
eugene
adsonarzw
eliciting
anticancer
evade
eur
httpirperegrineinccomeventscfm
establish
homes
abl
httpedge
employed
eric
hope
antibodyil
emd
else
adsadsonarcom
especially
homepage
hopes
antiangiogenesis
another
eventsrdquo
every
events
encouraging
httpstockchartscomhscuispphm
hpauk
httpstonsabiocom
higher
antiphospholipid
effort
httptinyurlcomabmw
enrolment
efforts
however
elemsrc
httpssecure
evaluated
https
advancement
announces
entry
encouraged
evaluation
hot
highquality
elemtype
hired
employees
explains
form
formerly
forms
guy
hamon
handbook
following
happened
forget
guptas
formulation
freddie
growthblocking
free
fragment
guide
aka
forum
aims
harsh
having
finalized
financial
financials
filter
fillfinish
affitechpphm
filing
hcc
financing
finding
haynes
focus
fold
flying
flip
finds
firm
fiscal
friday
growing
genentechs
generally
generating
genentech
gemtrmos
gemonlyn
adsonarjv
gemtreatment
goes
aacrncieortc
georges
gerbers
gerberthorpe
gets
geocappy
glioblastoma
generation
gives
googletagcmdpushfunction
garnicks
greater
functional
grants
grip
fullyenroll
ahead
agreements
fully
funded
granted
gpmm
game
agents
agentshellip
fye
agencies
fusion
aggressively
filed
fighting
hellipinvestors
amd
exposedpeimaging
amdcnv
explore
helliplocal
hellipjshan
exploit
exposure
hellipinterim
helliphellipthese
helliphellipthe
exvaleant
helliphellipup
externalization
helliphellipweve
expressionhellip
extended
hellipnuclear
aminophospholipids
helliprob
helliprgarnick
analyzing
helliprobert
exparexel
expansion
affiliated
helliproyalty
expectations
helliprdquowith
analysis
expertise
hellipon
hellipperegrine
experimental
expects
expedited
helliprdquoa
ambitious
helliphellipre
alliance
alert
fevers
aacrrsquo
healthcareconflondon
hear
fastest
alone
few
headreg
fhc
head
hcvhiv
fhbaviopticalimaging
headclinscience
headed
fhbavichemo
fhbaviimaging
abbottmenender
heavily
altimapemetrexed
facilitate
hellipdrthorpe
hellipest
facebook
hellipextended
exxoma
ezlibra
although
hellipcc
heirapparent
falsely
fanceostason
helenius
affitechnts
hellipaug
hellipaffitech
factsheet
advantages
developments
bans
client
clinicalregulatorycmc
clinicrdquo
click
barcelona
cityhopeduartecalif
clade
cleanest
clearance
clippednicked
close
cns
cnv
cofactor
coinventor
cmv
cmos
active
clotting
bannister
cmolocatorcom
barrow
citigroup
channel
channelurl
chart
basic
changed
chance
cell
center
certain
baumrsquos
charts
chasingthealpha
barrowphoenix
choroidal
chris
chronic
chirsquos
barton
chemo
chemotherapy
chi
chief
bacteriophage
coliganrsquos
augjan
auditorium
completing
compliance
augndash
comparing
avastin
authorities
comparator
compare
components
compositions
aucvauc
conducted
action
atthemarket
conclusions
conclude
comptrials
comscorepush
concept
concepts
companys
companyinitiated
colleague
color
background
combination
collaborators
backlog
bacteria
collaborate
backward
collaborating
combine
combined
activate
avastinpcphn
companies
avastinpc
activated
commercializing
come
comfortable
commenting
comments
ccr
cbdst
biosciences
bavipgnn
biotech
biotechnology
bioproduction
bioproc
biologics
baviribahcv
biopharmaceutical
bavips
biotechs
bla
bod
body
bavipcfrontlinembc
boehringer
bavipcnsclcfrontline
bmed
blackrock
block
blockades
blue
baviribavirinhepc
biodefense
beasley
benefits
benzinga
bestcase
begun
begins
beautifully
beg
begin
beginning
acute
bavisorafenib
bgprdquo
bavirsquos
binds
bioceo
bgpiindep
bgpidepen
bevacizumab
beyond
bglycoprotein
bgpi
booth
bounce
cancelled
baviarsenicimaging
candidate
candidateat
byr
bylaws
buyout
buypt
buys
buzz
capabilities
capacity
carries
cases
cause
caused
carlton
carlson
capetown
capps
capture
car
buying
bavicapecitabinerad
breastcancer
bring
bringing
bavimgmos
bavimono
bavipaclitaxel
bowl
brazilian
breakthrough
bavipcbreastfrontline
brokers
bronchs
burzynski
bavidoces
bavidocebreastrefractory
bavicp
bavigem
burns
bruce
actually
bavigemn
bungler
confer
conference
difference
differentiating
differs
digits
diagnosishellip
approvalhellip
abovefrom
dgetelementsbytagnamescript
approvals
diabetes
directly
directorqa
discuss
apparent
discussion
apoptotic
appid
discrepancy
disabled
disappointing
disclosed
discovery
development
develop
areas
delivery
accreditations
accomplish
deliver
definitely
decade
decision
deepak
define
demand
demographics
details
apr
approximate
approves
designation
apt
demonstrated
demonstrates
depending
archived
disorders
distribution
antitumor
antipsvhfs
dtra
antipsvhf
drthorpes
antivegf
drive
anywhere
drs
antivegfc
antipsplatform
dtratmt
duncan
dunn
duramycin
during
dukepphmhiv
dukepphmchavicavd
antipsmoa
dual
duct
dukehaynescavdgateschaviniaid
dream
dramatic
documentcookieindexofifsbr
documentcreateelementscript
documentgetelementsbytagnamescript
documentlocationprotocol
documentcookie
document
division
dmmmmyyyy
dnas
docealone
domains
donald
downstreamacting
doxy
doxyonly
dozen
dovetails
doubling
dosage
apoptosis
dosed
double
debttype
deals
correlation
adsonarpid
cosegregate
astonishing
correction
corporate
contrasts
cookie
astrochicago
copy
cosponsored
assisting
counter
countersues
countersuit
countries
counsel
asian
assessing
assessed
assess
aspects
contracts
achieved
conjugated
attendee
add
atr
conjecture
congresssdiego
attention
confirmation
confnyc
conforlando
connected
acquires
consultation
continues
asymmetry
contractpharma
consistent
considers
atm
connectfacebooknetenusalljs
httptinyurlcombjcj
acquired
counts
ascending
currenty
cutoff
cuts
dallasva
currently
current
around
ctls
curr
currapproved
dampen
adds
dcadlinkcolor
dcgi
ari
arenavirus
arius
achieve
dart
dataset
adequately
date
ctlcpbqfchartimgattrstylevar
ctlcp
artcleinterviews
crrsquos
crs
arrayabcdefghijklmnopqrstuvwxyzvar
cro
credibility
couple
courage
cowenboston
articles
crutcher
crystal
adding
ctlarmive
ctlbavi
arranges
ctlarmdoce
ctlarmcombined
csm
ctl
ctlarm
each
httpwwwperegrineinccomimagesstoriespdfscorpfactsheetpdf
reducing
redectane
refer
references
referring
referred
recurrences
recurrence
recently
recent
recognized
recombinantantibodies
recruiting
refs
regain
releases
relatively
relevance
rely
rem
relations
relapse
regional
regclin
registry
reiterates
reits
receiving
receives
quotescommentary
question
rabbit
radioisotope
raised
radiotherapy
quantservecomquantjs
qualities
pvalues
pvalue
qeventspush
qfyfye
qtr
raising
randomlength
reads
rdquothis
real
recaps
received
rbrekken
ratio
randomstringrandomlengthifrandomlengthrandomlength
randomlengthrandomlength
rapid
rare
rarely
remarkably
removed
scar
says
schroit
schroits
sciences
science
saying
saw
sales
sale
same
sandlere
sasync
scotsdale
sdstabledisease
sep
senior
sequel
seriously
service
selling
seek
sec
search
section
securitiesjason
seegenentech
safety
russian
resulting
resulted
reutelingsperger
reuters
reverse
revenuemonster
responsible
responseauthresponsesignedrequest
replays
repeatdose
reporting
represent
researchers
reversed
reversing
rpgn
rolf
rrdoghttptinyurlcomhbwzkq
rrnyc
russell
rodmanren
robust
rigorous
reviews
rim
rmason
road
pursue
pubs
pgmhellip
pfsmos
phage
phii
phils
phillip
pfs
pfizers
periods
period
pet
peter
pfizerferretti
phn
phosphatidylethanolamine
placebocontrolled
pjaffray
placebocontrolledhellip
placeboctld
platformhellip
pittsburg
piperjaffray
phpt
phosphatidylserine
physicians
pidr
pioneer
peregrinethorpebaviav
peregrineincists
pantophlets
pantginis
paper
parasitic
partnerable
particular
package
owned
outlined
outline
outnumber
outreach
overwgtptaacr
partnerdriven
partnered
pegs
pcalone
people
peptide
perc
pbbcfljcupla
pays
patents
parttime
pathogenesis
patientshellip
payable
play
plenary
products
producthellip
proj
projections
promotional
promise
prodrug
proapoptotic
presentsqbdcppscqas
presenting
previously
prhttptinyurlcomcosut
primary
prophylactic
proposed
prrussel
prpartialresp
psimaging
pstargetingrdquo
pubrdquo
providing
provided
protection
prostatecrpc
protein
protocols
provide
presentationsking
presentations
positionhellip
porton
positive
possibility
possibly
population
pop
poison
pneumonia
policy
polyreactive
pool
posted
posting
predictive
preclinpkg
prelim
prepared
presentation
pphmtoolong
pphmstason
poststream
posts
postsubject
potency
pphmduke
setting
settle
unequivocal
underway
unified
uninfected
untreated
unrealized
unblinding
unbelievable
ucalif
ualabama
uci
ucker
ultimately
upenn
upgrades
utswmcdallas
utswdr
vaccines
valeantdadgostara
value
utswdnaavanirlonza
utility
usachina
upstream
usc
uses
uspo
type
two
toolong
told
topshttptinyurlcommctb
toreturndocumentreadyfunctionulcharttabs
toxicity
towards
together
todate
tmttransformational
tmtdtra
tntbased
tntchina
tntimaging
tracers
trader
trying
true
tustin
tweets
twitter
trigger
trialsgov
trans
trades
transformation
treat
trialhellip
various
vasculartargeting
wilexiba
wiki
william
windowfbasyncinit
without
within
whos
white
welcome
weekly
werent
wgtavg
whereas
wks
wrikkelz
yearend
year
yet
yrend
yrs
yasg
yahoo
wwwtmticbdefenseorg
wwwdtramil
wyeth
xeloda
xfbml
web
wcoast
view
video
villaruz
virology
visibility
virus
vice
via
veas
vast
vegfr
vessel
vest
visit
vitro
want
wait
water
wave
wced
vspconly
vpquality
vladimir
vivatuxin
volume
vpclinaffairs
vpclinregaffairs
tmt
tmoodys
specialist
specbuypt
spectrum
spinoff
srproductdirregulatory
srdir
specbuy
sorely
soheila
soafrica
sole
someone
something
stage
stake
stimulating
stifel
stline
stockwiki
stonsa
stgmpmfg
std
started
stands
stason
statistical
statistically
smi
small
shown
should
shows
shs
signalseeking
sicker
shorter
short
shans
settled
sharesbut
shelf
shiv
signed
simple
slideshow
sks
slideshttptinyurlcomcebtwen
slowenroll
slower
skings
sitting
singlearm
simplifying
singlecatheter
singledose
siro
stonsas
streak
textjavascript
texas
them
theme
theres
themselves
testing
test
team
targeting
technology
temodarcurrsoc
terms
thestreet
theyre
tiein
through
times
tissues
titers
thrombus
thrombosis
thorpeetal
thing
though
thousands
thrilling
tarcevaerlotinib
tap
subsidiary
subs
substantial
suggests
suggett
submitted
subcutaneous
stride
stress
strongly
stvegas
sub
sui
suisse
survive
surfaces
table
taiwanese
taken
supreme
suppression
suitable
suit
supervising
supg
supported
outlandish
outer
httptinyurlcomybvu
httptinyurlcomybhl
httptinyurlcomyegxpvu
httptinyurlcomyevjq
httptinyurlcomyfylr
httptinyurlcomyfdgsom
httptinyurlcomyazk
httptinyurlcomyanfws
httptinyurlcomxdec
httptinyurlcomwudz
httptinyurlcomxwjk
httptinyurlcomxyd
httptinyurlcomyaefbj
httptinyurlcomygvtqa
httptinyurlcomyjmsod
httptinyurlcomyulw
httptinyurlcomyttt
httptinyurlcomyuxemu
httptinyurlcomyvypvh
httptinyurlcomyyegk
httptinyurlcomypd
httptinyurlcomynyfc
httptinyurlcomykxznha
httptinyurlcomykjy
httptinyurlcomykzbkd
httptinyurlcomylbefh
httptinyurlcomylevod
httptinyurlcomwtgc
httptinyurlcomwkpuc
httptinyurlcomqhzjh
httptinyurlcomqhvx
httptinyurlcomqjxxh
httptinyurlcomqkuwa
httptinyurlcomqyw
httptinyurlcomqwhzb
httptinyurlcomqgl
httptinyurlcompzs
httptinyurlcomprrkm
httptinyurlcompmcgsgp
httptinyurlcomptone
httptinyurlcompucqn
httptinyurlcompzlj
httptinyurlcomresos
httptinyurlcomrevm
httptinyurlcomvbax
httptinyurlcomvawjv
httptinyurlcomvvzfx
httptinyurlcomwazsp
httptinyurlcomwetxr
httptinyurlcomuztv
httptinyurlcomutya
httptinyurlcomrone
httptinyurlcomrfwrv
httptinyurlcomrxbps
httptinyurlcomrya
httptinyurlcomudkgr
httptinyurlcomyyhh
httptinyurlcomzcy
important
immunotherapies
improved
improvement
incr
inca
immunocytokines
immunity
iib
ihub
illustrative
image
immunereactivation
increase
indian
infiltration
infectivity
infoperegrineinccom
information
inhibit
infectious
infectionshellip
indicates
indias
indications
induce
infected
ihfbsr
ifu
httpwwwmlvcocommlvcoverageuniversehtml
httpwwwjmpgcom
httpwwwnasdaqcomsymbolpphm
httpwwwnexavarcom
zavoico
httpwwwperegrineinccom
httpwwwibclifesciencescomantibodyeng
httpwwwclinicaltrialsgovctshownct
httptinyurlcomzoj
httptinyurlcomzggo
httptinyurlcomzqn
httptinyurlcomzxqa
httpwwwavidbiocom
httpwwwperegrineinccomtechnologyoverviewhtml
httpwwwpiperjaffraycomcolaspxid
idctlihmainbodid
ichtntb
idea
ideal
ideally
ibc
hyclone
httpwwwvivatuxincom
httpwwwutsouthwesternedubrekkenlabresearchhtm
hub
humanized
hutchins
httptinyurlcompjqt
httptinyurlcompjovt
httptinyurlcomdyz
httptinyurlcomdmkwy
httptinyurlcomemda
httptinyurlcomeobdca
httptinyurlcomfczok
httptinyurlcomerhh
httptinyurlcomdmd
httptinyurlcomdjauo
httptinyurlcomdbsn
httptinyurlcomczhdq
httptinyurlcomdcnefa
httptinyurlcomddqh
httptinyurlcomdfyqcf
httptinyurlcomffc
httptinyurlcomfgzg
httptinyurlcomgzdg
httptinyurlcomgsshelhhsni
httptinyurlcomhcbw
httptinyurlcomhhln
httptinyurlcomhpydn
httptinyurlcomgkml
httptinyurlcomggcba
httptinyurlcomfjmpw
httptinyurlcomfhyzxz
httptinyurlcomfnnvk
httptinyurlcomfunn
httptinyurlcomfut
httptinyurlcomcycv
httptinyurlcomcuvo
httptinyurlcomcaxap
httptinyurlcombxfzu
httptinyurlcomcb
httptinyurlcomcgaxy
httptinyurlcomcjzfh
httptinyurlcomcjlbzn
httptinyurlcombxeat
httptinyurlcombwrat
httptinyurlcombmlpx
httptinyurlcomblrqk
httptinyurlcombnmpl
httptinyurlcombsgvm
httptinyurlcombtdbae
httptinyurlcomclhzbx
httptinyurlcomcmlkgs
httptinyurlcomcsdclwb
httptinyurlcomcrpug
httptinyurlcomcsjsl
httptinyurlcomcsmk
httptinyurlcomcum
httptinyurlcomcrlk
httptinyurlcomcqrupe
httptinyurlcomcnc
httptinyurlcomcn
httptinyurlcomcnghzyv
httptinyurlcomcoq
httptinyurlcomcosu
httptinyurlcomhryyj
httptinyurlcomhunqe
httptinyurlcommyqxw
httptinyurlcommxzbzm
httptinyurlcomndxtm
httptinyurlcomnfst
httptinyurlcomnkafwnl
httptinyurlcomnjycf
httptinyurlcommvzqn
httptinyurlcommtvdvl
httptinyurlcommk
httptinyurlcommhrtld
httptinyurlcommkmas
httptinyurlcommre
httptinyurlcommrfnsb
httptinyurlcomnnwt
httptinyurlcomnovgzk
httptinyurlcomoxrqysm
httptinyurlcomoboq
httptinyurlcomp
httptinyurlcompeqxrt
httptinyurlcomphqr
httptinyurlcomoaqp
httptinyurlcomnzwy
httptinyurlcomnqluq
httptinyurlcomnpnkp
httptinyurlcomnqqkm
httptinyurlcomntcm
httptinyurlcomnv
httptinyurlcommfw
httptinyurlcommcj
httptinyurlcomksx
httptinyurlcomkre
httptinyurlcomktkv
httptinyurlcomktvsb
httptinyurlcomkure
httptinyurlcomklpodc
httptinyurlcomkcpz
httptinyurlcomjbmkcg
httptinyurlcomjbba
httptinyurlcomjtnano
httptinyurlcomju
httptinyurlcomkbqo
httptinyurlcomkuuf
httptinyurlcomkxksl
httptinyurlcomltudso
httptinyurlcomltkmt
httptinyurlcomlxpb
httptinyurlcomlxtuo
httptinyurlcomlzygf
httptinyurlcomls
httptinyurlcomlptj
httptinyurlcomlgoras
httptinyurlcomlatcq
httptinyurlcomlgqmt
httptinyurlcomlmhkw
httptinyurlcomlnfn
inline
inside
moapotential
mmoption
mobile
models
modification
moderator
mmimmed
mmeuro
milestone
microbubbles
milestones
millions
mmatm
molcancerther
molecular
move
mourns
moved
mrpyou
mst
moshellip
moredifficult
monkeys
monies
mono
month
moody
michael
mice
measure
meaningful
mechanism
mechetner
meddirector
medarex
mda
may
marvin
martin
masten
matl
maxmm
medicine
medsurvival
message
merck
metaanalysis
methods
meyer
mention
menander
meet
medunivscarpi
mem
members
membrane
multinational
multiple
official
offering
older
oligodendroglioma
onyxbayers
onemedforum
offer
oct
obers
nyas
objective
observed
occurs
open
operates
origstyle
originally
orrrdquo
osis
otherwise
orig
organs
optimizing
opportunities
oralpres
order
org
numerous
numbers
neurosurgery
netmm
newsletter
nhsilltemd
nicolaus
nervous
negligenceserved
name
multmilestones
nasdaqcom
ndgen
nearly
nih
nihniaid
novdec
notloggedin
novembe
novndash
nuclear
nothing
notes
nmb
nls
noninferiority
normal
notauthorized
markets
market
jmpnyc
jmpconfnyc
joe
jrnlchromatography
jsid
jshan
jmp
jevtana
jeff
jclininvestigation
jeffery
jem
jerod
jssrc
judah
kerstin
keratitis
key
keynoter
kinglytleshaneso
keeptrying
keep
justify
july
kathryn
kda
keenan
jcappsperegrineinccom
janfeb
intl
interstitial
intrigued
intro
investigation
inventor
interhepatic
interferon
insidertrans
insideout
insight
inst
intended
investigator
investigators
itll
issues
ive
ivs
jan
iss
isolates
iphoneipad
investorshubcom
iressa
iressagefitinib
isolated
kingshangarnickmastenesolytle
kingshanlytle
little
lists
lloyd
load
longtime
loeschjco
listed
list
link
lilly
linkedin
lipid
lipids
lsquoimmunoindicativersquo
lucentis
mammalian
malignancies
manipulated
marik
mark
making
makes
lytle
luck
lytles
mahapatra
make
lifetech
lifehttptinyurlcomatlb
larry
language
late
later
latest
labs
labeling
know
knock
knows
lab
labeled
launch
lausanne
letter
leishmaniais
levels
licensee
licenses
leishmania
leases
ldquopotentially
lay
ldquothis
ldquowe
ldquowith
httptinyurlcombjowgh
ndline nsclc
phase iii
conf call
ceo steve
steve king
trial initiated
kings min
steve kings
clinical trials
liver cancer
topline data
philip thorpe
qtly conf
applications pstargeting
ist trial
robert garnick
min talk
httptinyurlcomyrwqm see
partnering discussions
ive seen
eop meeting
pstargeting antibodies
bull pgn
pphm news
protocol init
bavi arms
avid bioservices
mos result
extremely compelling
rob ringmaster
phil thorpe
cotarabrain success
trial design
phil thorpes
continue some
pivotal trial
medical need
usa cotarabrain
antiviral news
enrollment complete
esp mos
makes really
potential partner
antips antiviral
data compelling
potentially providing
update status
hutchins presenting
meeting fda
position ourselves
around pathway
article about
meeting communicated
fact still
posters pphm
unmet medical
approval point
exercise price
time major
hellip peregrine
parties they
particularly survival
healthcare confnyc
board participate
talk bioceo
hellipdr thorpe
hellipall think
partnering meetings
oncology discussions
one consideration
cancer vaccine
going very
cancer trials
orr pfsmos
given favorable
hard very
halflife days
case certainly
solid cancers
biopharmaceutical company
ndash see
peregrine receives
peregrine pharmaceuticals
bavidoce ndline
efficient path
far exceeded
msg follow
time still
things need
been working
next steps
clinical imaging
clinical data
news peregrine
hide intro
being considered
clinical trial
high dose
most importantly
mlvs george
working towards
look forward
door potential
presented aacr
preclin data
pphm srb
data presented
would ideal
interim data
kingshangarnicklytle transcript
also sparked
doubling mos
addl parties
which means
large area
viral infections
pts bull
dose arm
interest goal
weve seen
just matter
accelerated approval
quote filter
data continue
joins pphm
lung cancer
less than
antibody therapeutics
regulatory standpoint
proposing meeting
press release
raises pphm
were administered
data ive
data like
forum contact
fpdsgov httptinyurlcomjbmkcg
ftms charts
firm httptinyurlcomhryyj
filing httptinyurlcommutbungler
drthorpes min
dream through
fortunate someone
friend peregrine
dream bringing
filed fda
frontlinehepc randomized
fink ceo
frontline nsclc
drug safety
forex prices
frontline lung
dozen leading
firmly establish
follow his
following advantages
drug highly
final results
folkman rdquothis
fiscal year
focus commercializing
financial results
findings still
drug designation
first new
final data
drug ndline
findings suggested
following pphms
following discussions
firstinclass pstargeting
drug nsclc
drug class
future development
general counsel
documentcreateelementscript elemsrc
distribution different
generating lot
generation pstargeting
genentech studying
documentgetelementsbytagnamescript sasync
gbm tnt
gbm therapy
gemtreatment pancreatic
documentgetelementsbytagnamescript scptparentnodeinsertbeforeelem
gend singlearm
dispute httptinyurlcomksx
gerberthorpe immunotherapy
disorders cancer
goal elim
diseases hepatitis
goal pursue
goal start
disorders one
global prod
give hard
given close
gives avid
gives indication
gbm patients
documents help
future biopharm
funding agencies
field represents
futureapproved antips
gallery advanced
fund operations
fund letter
fully human
fullyhuman bavipgnn
fullyhuman bavituximabnat
fullyhuman ipgn
doubled mos
gammagard rhuph
donald senger
garnick saw
garnicks work
garovoy exxoma
gbavituximabformerly tarvacin
garnick like
dose bavi
doubleblinded placebocontrolledhellip
garnick its
double generally
garnick joined
downgrades pphm
feel strongly
evilevitch exnovartis
ebola virus
evilevitch exparexel
ebola httptinyurlcomaaxl
exceeded expectations
evidence discrepancies
everything immunocytokines
evaluating bavi
evaluate panel
evaluating possibility
events mos
educational educational
excellent opportunity
eastern capital
eager meet
early comp
expand antipsvhf
during diaca
expanded jan
execs yoshiokarichierieso
exec info
excerpts httptinyurlcomwque
excerpts cjgaddy
excited bavituximabs
easier approach
excluded totally
euros rem
europe httptinyurlcombwrat
enough diff
efficacy data
enrolled oct
enrollment begins
efficacious producthellip
endless part
end april
efforts new
effort fda
efficacy requirements
eio prepared
elegere although
efficacious clinical
enrollment taking
etf center
essentially completely
effect adding
educational videos
eur licensee
essentialhellip prepare
effect profile
entry point
eric swartzs
especially exciting
effects patients
duramycin binds
expanding desire
fastest route
drugs infected
favorable results
favored pathogenesis
fda about
drugs patients
failures httptinyurlcomdfyqcf
duct lung
fact even
dtratmt govt
fact viruses
factors between
drugs httptinyurlcomcosu
drugs direct
fevers httptinyurlcomdxpup
drug tarceva
few far
few more
fhbavi joined
feuerstein falsely
fda oks
fda approves
fda conduct
fda historical
fda meeting
fabrsquo fragment
exvaleant httptinyurlcomwysxm
expedited meeting
expects announce
experience drug
experimental animals
explore these
expecting show
expected vest
going able
expect enroll
expected amended
expected open
expected survive
dukes bhaynes
explored bavi
dukepphm jem
dukepphmchavicavd hiv
dukehaynescavdgateschaviniaid hiv
extended teams
extraordinary stroke
dukepphmhiv candidate
dukepphmhiv candidateat
expression system
extend medsurvival
extended existing
extended survival
fhc dev
hellip ceo
imaging human
imaging bavituximab
imaging antiviral
imaging radioisotope
imaging tracers
immune checkpoint
imaging using
imagine given
images quite
ideal combination
idea sign
ihub facebook
iib registrational
iii trial
iii pivotal
immune response
immune responses
inc fargo
inc about
including most
including treatment
increases immune
increase ultimately
improvement mos
improved cponly
immunity investigators
immune system
immunology journals
immunopet imaging
important since
important part
idctlihmainbodid classpageclr
ibcconf httptinyurlcomypd
httptinyurlcomybvu hellipsk
httptinyurlcomyazk hellipdr
httptinyurlcomyanfws hellipperegrines
httptinyurlcomyfdgsom hellipthe
httptinyurlcomykxznha hellipsk
httptinyurlcomynyfc bavituximab
httptinyurlcomylbefh hellip
httptinyurlcomxyd nasdaq
httptinyurlcomxwjk hellipphilip
httptinyurlcomvluj sept
httptinyurlcomtzen plos
httptinyurlcomvqk helliphellipup
httptinyurlcomwrq hellipjshan
httptinyurlcomxb stonsas
httptinyurlcomwrrso hellip
httptinyurlcomyzfwyv hellipdr
httptinyurlcomzqn ocbj
hub dailyhomelog
httpwwwutsouthwesternedulabsbrekken yahoo
human safety
human trials
ibc bioproc
humans antibodies
httpwwwsecinfocomdvpuavdhtm poison
httpwwwpiperjaffraycomcolaspxid jmp
httpwwwaffitechcominvestorsnewspressreleasesenglish antiangiogenesis
httptinyurlcomzxqa disclaimer
httpwwwavidbiocom peregrine
httpwwwibclifesciencescombpi oct
httpwwwperegrineinccom corp
httpwwwnexavarcom protocol
ind clinical
ind fda
ist indications
issues been
iss httptinyurlcompjcbw
ist nsclc
ist pgm
ist program
ist phiii
iss httptinyurlcomcuqry
ipgn fhbavi
inventor pstargeting
invention suitable
investigators either
involved other
ipgn fab
involving brain
ists very
its cotara
joins peregrine
joe said
jrnl httptinyurlcomanmaa
jshan vpclinregaffairs
just build
july peregrine
job vacancynet
jem httptinyurlcomyzrtax
its merckkgaas
its going
jaffraycharles duncan
jay carlson
jem dukepphm
jclininvestigation article
intriguing concept
intrigued see
infoperegrineinccom upcoming
info might
inhibit hiv
inhibitory activities
init comp
inhibitory antibodies
infiltration breast
infections using
indian cotarabrain
indep thirdparty
indication received
indication specifically
infected cells
induced externalization
initiated uci
institutionshellip peregrine
into clinicrdquo
interview baviav
into further
into more
into pivotal
into phase
interstitial catheter
interferonfree treatments
interactions fda
intended confirm
interest those
interest upd
interferon replacement
interesting about
httptinyurlcomtxsks helliprob
httptinyurlcomspffd info
helliphellipwe sufficient
helliphellipre ndlinensclc
hellipgenentechgarnickchamowsuggettmasten abbottmenender
hellipinvestors should
hellipnuclear medicine
hellippphm recently
hellipperegrine launches
hellipfollowing affitechnts
hellipdr garovoy
hellip thorpe
hellip stonsas
hellip wyeth
hellipaps antiphospholipid
hellipceo steve
hellipas shorter
helliprdquowith less
helliproth ceo
higher radiation
high doses
highly encouraged
hints future
his gbm
his firstever
herpes aikifredicist
herpes acute
hellipsking retmt
hellipsk resp
hellipwe believe
help faq
hemorrhagic feverutexas
help forum
hellip robert
hellip phb
group coding
great promise
great pgmhellip
guessing game
guest web
halozymes cmos
guptas cns
great news
great interest
going forward
going double
grant research
grant work
graphs httptinyurlcomwudz
granted antips
hamon center
harsh side
hellip ascorsquointerim
helenius chris
diseases believe
hellip fda
hellip nih
hellip more
heavily symptomatic
healthcareconflondon httptinyurlcomwqam
haynes refs
having corporate
head medical
headreg nsclc
healthcare conf
headreg qtlycc
historical measures
history since
httptinyurlcomlqbdkt also
httptinyurlcomkvplmj detail
httptinyurlcomkrxk full
httptinyurlcomlxpb mda
httptinyurlcomlxtuo hellipthe
httptinyurlcommhrtld hellipsk
httptinyurlcommegkre hellipsking
httptinyurlcomklpodc hellipdr
httptinyurlcomkassc hellipsking
httptinyurlcomfjmpw hellipto
httptinyurlcomfgjd biosimilars
httptinyurlcomfpgngu hellipcsm
httptinyurlcomfzubz hellipdrthorpe
httptinyurlcomhezkux hellipaffitech
httptinyurlcomgoz hellipinterim
httptinyurlcommk pending
httptinyurlcommlbse smi
httptinyurlcomqhvx jill
httptinyurlcompzs hellipsteve
httptinyurlcomqjxxh final
httptinyurlcomresos bavi
httptinyurlcomrfwrv hellipsk
httptinyurlcomrfwrv hellipdr
httptinyurlcompzs hellipadtprostate
httptinyurlcompmcgsgp hellipldquoprimary
httptinyurlcompeqxrt bull
httptinyurlcommyqxw hellip
httptinyurlcomphtty comp
httptinyurlcompjovt bull
httptinyurlcompjqt tumor
httptinyurlcompjqt iii
httptinyurlcomeelvw study
httptinyurlcomdynlzr hellipon
httpirperegrineinccomeventscfm augndash
hrresults note
httpirperegrineinccomeventscfm dec
httpperegrinetrialscom bavi
httptinyurlcomaeyxj importantly
httpstonsabiocom harry
hot stockwiki
hot breakout
hiv full
hiv collab
holdings nasdaqcom
holds promise
hopes bavi
hope excited
httptinyurlcomalhx another
httptinyurlcomavred hellipto
httptinyurlcomdcnefa hellipmm
httptinyurlcomcycv expert
httptinyurlcomdjw pphms
httptinyurlcomdlpjm insidertrans
httptinyurlcomdnmpe full
httptinyurlcomdnmpe dukes
httptinyurlcomcwodb hellip
httptinyurlcomcsjsl also
httptinyurlcombjowgh peregrine
httptinyurlcomawg hellip
httptinyurlcombtzkwl hellip
httptinyurlcomcgnkvpa bull
httptinyurlcomcnqxoh data
httptinyurlcomcmlkgsk httptinyurlcomhedbaf
going discuss
detailed results
avid selected
avid gets
avid expands
avid signs
award antips
back thealias
aware look
avid drive
avid completes
avastin which
avastin bevacizumab
avastinpcphn stage
average placebo
avid cmo
avid becomes
backlog thru
bart haynes
bavi induces
bavi httptinyurlcomyaefbj
bavi herpes
bavi into
bavi moa
bavi phb
bavi oncology
bavi cancer
bavi broad
based these
based orr
basic research
basically take
baumrsquos report
basically would
authorities its
atthemarket sales
article jrnlchromatography
article httptinyurlcomvmf
article httptinyurlcommlgzp
article molcancerther
article peregrine
article preclin
article pgs
article httptinyurlcombsgvm
article highlights
article ccr
arseniclabeled bavi
article cleveland
article cotaragmb
article fhbaviopticalimaging
article exposedpeimaging
arvoftlaud httptinyurlcomqkuwa
ascending dose
astrothoracicchicago httptinyurlcomwrrso
astonishing amount
atm agreement
atm fundraising
attendee reports
atr research
assets chart
assessment approved
asia httptinyurlcomlatcq
asco cotaraph
asian populations
assess bavituximabs
assessing patient
assessed antiinfective
bavi weekly
baviav collaborators
bioseminar httptinyurlcomrone
bioreactors httptinyurlcomqgl
bioprocess intl
bioservices inc
biosimilars area
biotechnology article
biosimilars services
biopharmdevprodweek httptinyurlcomcjzfh
biopharm inc
binding antihiv
bind directly
biodefense efforts
biologics demand
biomarkers evaluated
biology genentechs
biotechs tntchina
bioworld artcleinterviews
both bavi
board recs
board before
both innate
both lipids
both vegfr
both potential
board affiliated
blood vessels
bla submission
bioworld today
blackrock inc
blockades session
blood clearance
blood cells
biggest unpartnered
bhaynes targeting
bavituximab arms
bavituximab advances
bavis pronged
bavituximab breaks
bavituximab inventor
bavituximab unique
bavituximab pgm
bavis potential
bavirsquos day
bavidocebreastrefractory repga
bavichemonsclc httptinyurlcomgzdg
bavimgdoce arm
bavimono repeatdose
baviribahcv trial
bavinsclc study
bavituximabs moapotential
because believe
benefits treating
believe question
between cotara
bglycoprotein bgpi
bgprdquo granted
bgpi binding
believe market
believe could
because shows
because huge
been affected
been observed
being studied
being see
arranges direct
around potential
after each
after data
after cotara
after market
against cancer
agencies promising
against lassa
affitechpphm collab
affitech sublicenses
advice internetforumuser
advancing program
affairs rob
affitech press
affitech signs
affitech reiterates
agency well
agil httptinyurlcomoaqp
alive today
alerts trades
alerts commodities
already begun
also avid
also contrasts
also binding
alan esptein
aka pgn
agreed good
agreed fda
agreed provide
agreement represents
aids vaccine
aids commenting
administered monkeys
adequately address
absolutely unbelievable
absolutely nothing
absolutely chock
accomplish goals
acted host
activated cells
activate antiviral
abovefrom john
above trials
aacr pts
aacr brekken
aacr tumor
abl max
about accelerated
able take
active boards
activities right
addition peregrine
added trialsgov
addl animal
addl data
adequate dose
adds pphm
added httptinyurlcomzggo
added formerly
activity vivo
activity ticker
actual product
adam yopp
add pphm
adaptive immune
also exp
also listed
appointed chairman
applied approval
app stockwiki
approach toward
approach treatment
approval intention
approval fda
app ihub
app antilipid
antiviral methods
antiviral capabilities
antiviral pgm
antiviral research
apoptotic tumor
anywhere near
approval its
approval process
arm were
arm difference
arm comparing
arms bavir
arms comparator
arms into
arms compared
arm analysis
arenavirus hiv
approve trans
approvals httptinyurlcomctzp
approximate results
archive other
arena aggressively
areas really
antiviral agent
antiviral activity
another order
annual shms
annual mtgftlaud
antibodies different
antibodies specifically
antibody eng
antibody also
annual mtgboston
anionic phospholipids
ambitious goal
also potential
aminophospholipids httptinyurlcompdny
analysis results
animals progress
analyst andrew
antibody homes
antibody platform
antipsvhf studies
antipsplatform biopharm
antitumor activity
antitumor effects
antivegfc bull
antivegf mab
antips tumor
antips fusion
antibodyil immunocytokine
antibody portfolios
anticancer news
anticipating being
antips data
antips antibodies
brain cancer
brazilian collabs
csa addl
crystal research
crutcher pcrutch
csm over
ctl countersues
ctlarmdoce end
ctlarm majority
crpccastrationresistant prostate
crpc ist
cprit httptinyurlcomcsmk
coverage broad
created lot
credibility honestabe
cro gbmcotara
credit suisse
ctlcp mos
ctri registry
cuttingedge pharmaceutical
cutoff httptinyurlcomysfed
cutoff bavi
dampen enthusiasm
dart adds
data announced
data accreditations
currenty halted
currently evaluating
curr buy
curious still
curr specbuy
currapproved linensclc
currently demonstrates
current pphm
countries stasonstonsa
could opening
corporalagarn about
corp corp
copy just
corporate courage
corpupdate mmatm
correlation support
correctly whereas
controls tumor
control arm
considers his
connectfacebooknetenusalljs refparentnodeinsertbeforejs
continues show
contract httptinyurlcompjqt
contrast agents
contractpharma article
cosegregate normally
cosponsored trials
cotaragbm trials
cotaragbm singleinfustion
could avoid
could become
could much
could effective
cotarabrain trial
cotara wced
cotara demonstrated
cotara brain
cotara ichtntb
cotara poster
cotara represents
cotara regulatory
data cbdst
data china
diag httptinyurlcomdue
dia only
development commercial
diag httptinyurlcomofsv
different antivirals
different potential
different phospholipids
developing new
dev russiabrazil
design plan
design approval
design submitted
designed assess
determining role
desire compare
different qualities
differs avastin
disease httptinyurlcomju
discussions fda
discussed qtly
disease space
disease symposium
disease which
disease very
discuss same
discrepancies isolated
disappointing grateful
director regulatory
disc news
disclosed before
discrepancies found
discovery grant
describes using
described feel
data suggest
data provide
data problems
data supporting
dataset product
david ucker
david gerber
data phii
data nor
data ctlarmschemo
data consistent
data date
data error
data ldquobavigem
data httptinyurlcomblrqk
days range
dcreateelementscript jsid
delivery radiation
delivery pub
demand httptinyurlcomchuyo
demographics baselines
describe clinical
demonstrated significant
defense fighting
deena beasley
deal httptinyurlcomkure
deal httptinyurlcomkkvddt
dec expect
dec fyq
dec nature
dec job
conjugated antipsma
conjecture most
catalyst biosciences
car liked
capability cmolocatorcom
cathetershttptinyurlcomczjymf hellipsk
cause lifethreatening
cbd httptinyurlcomkbqo
cavdgates hivvaccine
capabilities delivering
cancers usa
cancer treatment
cancer therapy
cancerfighting immune
cancerhcc openlabel
cancers trial
cancers india
ccr aacr
cell biology
chance some
chamow exgenentech
cfo paul
chart httpstockchartscomhscuispphm
chavi newsletter
chemistry world
cheaper sharesbut
certainly hope
certainly before
cell lipid
cell division
cells evade
cells stress
ceo skings
ceo sking
cancer peregrine
cancer openlabel
brokers educational
broke didnt
broadspectrum capabilities
build really
bull examples
business development
busdev strategy
broad potential
bring significant
breakthrough designation
breach contract
breast cancer
brekken httpwwwutsouthwesternedulabsbrekken
brekken pphm
brekken phd
business frustrated
business including
cancelled protocol
call kingshanlytle
cancer hellip
cancer hellipyour
cancer httptinyurlcomttlne
cancer httptinyurlcompobktc
call kingshangarnicklytle
call kingshanesolytle
buyout offer
buying streak
buys arius
call httpirperegrineinccomeventscfm
call kingesolytle
call httptinyurlcomqhzjh
chemo orr
chimera research
companies drug
comp coming
comp bavichemo
companion diagnostic
compare mosmos
complete httptinyurlcomvvzfx
compared other
commodities forex
commercial supply
combinations previously
combination other
combinationtherapy potential
combined bavirsquos
comments about
come those
compliance ceo
compositions treating
confnyc httptinyurlcomwtgc
confirm cotaras
conforlando httptinyurlcomvexcl
confusion osis
congresssdiego httptinyurlcomuvrgr
congressrdquo boston
confident enough
conference capetown
conf httptinyurlcommfw
conduct rigorous
conf httptinyurlcomutya
conf httptinyurlcomycrrwub
confer tumorspecific
conf nyc
combination full
collaborators sking
clinical pipeline
clinical dev
clients prepare
clinical potential
clinical program
clinical sites
clinical results
click latest
clearly lot
chirsquos ldquothe
china shanghai
choosing mobile
choroidal neovascularization
clade hiv
chris reutlingsperger
clinical strategy
clinical supplies
coding discrepancy
cocktails httptinyurlcomnovgzk
collab httptinyurlcommaggy
collab tnt
collaborators already
collaborating catalyst
cns httptinyurlcomkvca
cmo subsidiary
clinpharm peregrines
clinically they
clippednicked bgpi
close consultation
cmo boehringer
cloud top
diseases based
lead end
speed cancer
specifically tumor
specifically target
sponsored trials
spread several
srb presents
squamous bavi
species simplifying
speakers alan
some lipids
solid tumors
sorafenibliver fhbaviimaging
sorely missed
space avid
spa special
srproductdirregulatory joins
stands just
sticky hide
steven chamow
status true
stifel wilex
stifelnicolausboston httptinyurlcomcrpug
still reached
still alive
status pphms
stats new
starting phiii
starting look
stason inks
stated goal
statistically significant
statements duke
small molecule
slowenroll new
singledose hcv
singlearm trials
signs efficacy
sitc poster
site added
sites expect
sites added
significant unrealized
significant promise
showing fold
show statistical
shown promise
sicker ecog
signalseeking nsclc
side far
sites goal
sites per
slide considerable
sks slideshow
slide youll
slides incl
sloan case
slides showing
sking rrnyc
sking rothocdanapt
situation investigation
sitting today
sking goal
sking ldquothis
sking reported
sking ldquowe
still several
stimulating moa
survived more
survival results
survival potentially
symposium httptinyurlcomgl
symposium httptinyurlcomqy
table showing
system fight
survival eventsrdquo
survival advanced
supply agreement
supg moving
support avids
support moving
surfaces inhibit
surface plasma
take forward
take lot
tap power
talk onemedforum
targeted approacheshellip
targets therapy
technolody medarex
tarvacin cleanest
talk nyas
talk needham
taking advantage
taken over
taking longer
taking very
talk jmpnyc
talk incl
sui shen
sufficient support
streamer level
strategy financing
strategies eliciting
stride again
strong ndline
studies enhance
studies conducted
straightforward measure
story nabtt
stock market
stock conf
stock warrants
stockpile part
stonsa biopharm
stone httptinyurlcomfnnvk
studies plos
studies showed
substantial prolongation
subsidiary suit
such anti
such lsquobetabodiesrsquo
sufficient justify
sues csm
subcutaneous herceptin
studying pstargeting
studies well
studies side
study chi
study could
study shows
study discussed
should recognized
should add
represent final
reports fourth
reporting data
require cofactor
research article
research points
research funding
report theme
report httptinyurlcomltudso
remaining issueshellip
remaining engaged
remains init
remarkable results
report fourth
removed critical
research utsw
researchers bavi
results could
result since
responses insideout
results only
results really
results shared
results seen
responses httptinyurlcomcwodb
responserdquo httptinyurlcommvzqn
researchs lead
researchers establish
reside peregrine
response both
response therapy
response rates
remain negotiated
relevance new
receiving widely
receive accelerated
recdmm httptinyurlcomphqr
recently filed
recombinantantibodies conf
recruiting washunivsmstlouis
reconstitution occurs
recaps ndlinensclc
really very
reads orr
reached mos
real interesting
really counts
really part
really looking
rectal initiated
recurrence additionally
registrational path
registration pathway
regulated aspects
regulatory agency
relapse indias
regulatory strategy
registration clinical
region mouse
refer trial
reducing toxicity
refractory patients
refrsquod aacrrsquo
regclin strategy
regain nasdaq
reversing suppression
review able
see thats
see httpwwwjevtanacom
see httpperegrinetrialscom
seehttpwwwperegrineinccomtechnologybavituximaboncologyrecentdatahtml ftms
seek accelerated
seen lot
seen both
see diagnostic
securities life
sec filings
sdstabledisease red
secondline nsclc
secret weapon
secure regional
secure partnership
seen prior
selectikineradnsclc httptinyurlcompzlj
shans min
shanghai medipharm
shapiro barrow
shareholders meeting
shelley suggett
shares shares
several important
settle httptinyurlcommhgcg
services deal
sequel eyebuystox
services feeforservice
set mobile
setting results
setting imaging
screener news
science httptinyurlcombgglxj
rober rmason
rob garnick
road think
robust data
rodmanren jaikariabenjamin
rolf brekken
role rsquo
rituxan herceptin
rim also
reviewhellip rob
review httptinyurlcomansqcea
rhuph signed
right which
rigorous randomized
rights certain
roth confdanapt
roth talk
sale nls
saidi thousands
sales byr
sanofiaventis jevtana
schroits patents
saw earlier
safety profile
russian partner
rothocdanapt httptinyurlcomqym
roth ups
rsquo httptinyurlcomkqeg
rstupp httptinyurlcomfut
russia httptinyurlcomhhln
rule which
technologies httpwwwperegrineinccomtechnologyoverviewhtml
technology platform
various settings
var scpt
var qevents
vast number
veas pegs
vegfr compared
vegf pioneer
var elem
var dcpublisherid
valid even
vaccines after
valuable new
value company
var comscore
var alphabet
vegfrgel presented
very active
vhf pgm
vessels induces
vessel marker
via targarosenblum
video semper
viral infectionshellip
videos news
very very
very preferential
very comfortable
very beautifully
very confident
very difficult
very nicely
very disturbing
vaccine elicits
utsw parklandhosp
until they
univark cityhopeduartecalif
univ pittsburg
untreated genotype
upd httptinyurlcomnzwy
update freddie
upd httptinyurlcomowsjqzt
unique mechanism
uninfected cells
types particular
type virus
ucker ari
under avid
understanding tarvacin
under contract
update jerod
update thru
usc httptinyurlcomcn
usachina firm
used cotara
used some
utsw mda
using zrpgn
usa phb
upstream immune
updated numbers
updated clinical
updated qtly
updates bavituximab
upitt report
upgrades resp
viral infectivity
viral membrane
whos registry
whollyowned mfg
wholly owned
wilexiba germanybelgium
wins bioproduction
without induction
within orphan
whole new
while news
which only
which important
which showed
which were
while continuing
while bavicp
without partners
work together
wwwtmticbdefenseorg dtra
would take
year could
yearend fiscal
yrs httptinyurlcommhboa
yrend httptinyurlcomkyas
would support
would predictive
working ceo
work whole
would been
would big
would obviously
would look
which help
which goal
wayshellip more
water systems
vta research
websites httptinyurlcomagwno
wed posters
well data
wed reached
vta licensing
vspconly httptinyurlcommrya
virology they
viral trials
viruses exemplified
visit peregrinetrialscom
vpquality httptinyurlcomqxuvso
vpclinaffairs jshan
well expanding
well support
werent told
werent able
weve been
weve laid
which could
which carries
were very
were sitting
were alan
welschof discusses
were currently
were doing
were referring
were pivoting
twitter ihub
tweets httptwittercomsearchqpphm
thorpes project
thorpes patents
thorpes apt
those potential
those results
thrombus issues
though reached
thorpersquos heirapparent
thorpemayo antips
think time
think bestcase
thorpe article
thorpe developing
thorpeetal antips
thorpe utsw
thru fdas
thru fyq
tnt technologies
tnt interim
tntbased european
tntcytokine fusion
tools charts
together lack
tnt china
tmtdtra extend
thus makes
thru partnering
time eop
time join
time seek
time publicly
thing fact
they smaller
therapeutic indications
therapeutic discovery
themselves outer
therapeutics diagnosticshellip
therapeutics huntingtonbeach
therapies interesting
therapeutics treat
them based
thats these
temodarcurrsoc httptinyurlcoms
teknuloof cjgaddy
terms penetrants
texas cprit
than mos
than expected
therapy more
therapy nsclc
these specific
these recent
these truly
these types
they recognize
thestreet pphm
these ists
these drugs
therapy tntcotaraveas
therapy play
therapy well
therehellip lot
these discussions
theres nothing
top lists
top selling
trials httptinyurlcomplm
trials date
trials completed
trials init
trials ist
trials see
trials link
trials archived
trials above
trial provided
trial protocol
trial sufficient
trial update
trialhellip rob
trial using
trials stline
trigger krakonos
tumor than
tumor immune
tumorinduced immune
tumors httptinyurlcomcwodb
tumors weve
tumors httptinyurlcomjbfl
tumor imaging
tumor httptinyurlcomqjug
trrs pfs
triggers conclude
true jssrc
true ssrc
tumor growth
true xfbml
trial originally
trial open
treated tumor
transformation httptinyurlcommywww
transcript httptinyurlcomphqr
treating cmv
treating higher
treatment arm
treating lassa
transcript httptinyurlcomkyas
transcript httptinyurlcomkhpokw
toreturndocumentreadyfunctionulcharttabs lilastchildaddclasslastct
topline orr
toxicity show
transcript httptinyurlcomabmw
transcript httptinyurlcombxeat
transcript httptinyurlcomapc
treatment highlights
treatment major
trial httptinyurlcomtagpz
trial httptinyurlcommcj
trial init
trial matl
trial ndline
trial most
trial httptinyurlcomeobdca
trial evaluate
treatments type
treatment protocols
tremendous potential
trial bavipemcarbo
trial enrollment
trial because
rather likely
rate high
move vta
move programs
move product
moving ahead
moving these
multmilestones asm
much utility
move closer
mourns loss
most read
most intrigued
most recently
most remarkably
motivated than
most thrilling
must determine
name bavituximab
netmm httptinyurlcomotmt
nervous systems
neoplasia article
network httptinyurlcomlnfn
neutral buy
new approach
new agent
negligenceserved httptinyurlcomazrgys
near term
nanoparticles which
nanoparticles load
nasdaq pphm
natural antibodies
nature medicine
natural tiein
mosmos pcalone
mosmos bavimg
moderator moderator
models highly
models disease
modification everything
molecular imaging
mono repeatdose
money thru
model bavi
model acute
mlv reits
mlv filed
mlvgeorge zavoico
mmeuro ibc
moa bavituximab
mmimmed mmoption
month httptinyurlcompn
moody antilipidspgn
mos mos
mos helliproths
mos nsclc
mos reported
mos yet
mos think
mos gemmos
mos docealone
more than
more regulatory
mos bavimgmos
mos combine
mos data
mos ctlarmcombined
new arrayabcdefghijklmnopqrstuvwxyzvar
new class
numerous viruses
numerous phase
number virus
nyas antips
nyc nyasorg
oct httptinyurlcomcgaxy
obtained companyinitiated
nsclc trials
nsclc trial
nsclc httptinyurlcomkuuf
nsclc clinical
nsclc nsclc
nsclc phb
nsclc review
nsclc randomized
ocular posters
offer additive
operates avid
operate new
ophthalmic formulation
opportunities including
opportunity collaborate
opportunity acquire
openlabel arm
opened door
oncology httptinyurlcomvcnbz
official close
one unified
ongoing bavidoce
ongoing trials
ongoing potential
novel therapies
novel monoclonal
new vivatuxinmicrowaveablation
new therapy
new product
new wave
newly funded
news live
news correction
new information
new immune
new combinations
new clinical
new control
new development
new found
new diverse
news nsclc
next decade
note capecitabine
note cabazitaxel
noteworthy since
novel antibody
novel brain
novel antiviral
nor been
nmba article
nhsilltemd httptinyurlcomyudpw
nhsillt emd
niaid grant
niaid lab
nice bounce
niaid reviews
mktperform httptinyurlcomdmd
mixup httptinyurlcomfpgngu
licensing agreement
licenses antivegf
licensee httptinyurlcomzcjqr
licensing revenuemonster
lifetechcapsteve dunn
like future
like buying
license agreements
lic pphm
leishmania infection
leastdilutive company
leishmaniais protozoan
less chemo
levels mst
let past
like georges
like new
liver interhepatic
live charts
lloyd dunla
loan mmimmed
long these
long history
little staining
little peptide
like study
like out
link httptinyurlcomntcm
linkedin right
lists peregrine
list top
zrpgn seegenentech
ldquothis highly
keynoter recombinantmabsbarcelona
key regulation
keratitis see
keynotes bavips
king head
king said
king qtlycc
keratitis betabodies
kenneth dart
justify moving
just youd
kathryn hansen
kda longer
keeptrying jakedogman
kda they
kinglytleshaneso transcript
kingshangarnicklytle transcripthttptinyurlcomcosut
launch facility
last couple
launch peregrines
lausanne switz
ldquoindep cancer
lawsuit against
large multinational
labs ctl
knows corporalagarn
knock disease
kraws httptinyurlcomdjauo
kurilla mention
labs abl
lab team
longtime colleague
look into
mechanisms bavituximab
mechanism immune
mean dose
mechanisms sorafenib
mechetner formed
medical technologies
meddir execute
mbc initiated
may better
market standpoint
mark ziebell
markets advance
markets were
maturation caused
masten exgenentech
meet fda
meeting httptinyurlcomlmhkw
might manipulated
michael lilly
millions cancer
minbid compliance
missag parseghian
minyanville article
mice even
mgkg armhellip
members recent
meeting thru
menander exabbott
merck kgaagermany
mfg subsidiary
methods treating
marik immunopet
map handbook
lowdose arms
low single
low dose
lung pancreatic
mab demonstrated
mabs antips
mab pgn
loui exgenentech
lot time
looking very
looking number
lot great
lot interest
lot those
lot into
mabs cjgaddy
mabs immune
management inc
making antiviral
manufacturing innovative
many new
many times
many people
make judgment
majority patients
mabs stimulate
mabs incl
macrophages theyre
made fully
major solid
mahapatra most
optical imaging
optimal registration
pphm website
pphm tustin
pphm set
pphmduke jem
pphms apts
pphms homepage
pphms dtra
pphm review
pphm presents
pphm files
pphm comments
pphm hires
pphm httptinyurlcomqctos
pphm preclinpkg
pphm licenses
pphms srb
pps ask
presents avids
presents antipsvhfs
presented future
presents new
presents stifel
pretty dramatic
presents tnt
presented asco
presentations other
preclin dev
pps going
preferably before
prelim data
presentation late
present its
pphm board
potentially used
posted response
posted most
post giving
poster aacr
poster aacrncieortc
posters presented
poster bavismoa
possibly prophylactic
possible addl
portfolio which
point were
porton downuk
positionhellip moreover
possibility making
positioning bavi
posters world
postsubject older
potential illustrating
potential growing
potential ndgen
potential other
potentially approach
potential partners
potential feel
potential detection
potent mab
potency wholecell
potential anywhere
potential broad
potential companys
potential cancer
prevention vhf
previous posts
pstargeting preclin
pstargeting platform
pstargeting mabs
pts presented
pts todate
public comments
pub uspo
pstargeting mab
pstargeting clinical
provides contract
provided these
provides update
prrussel rebalance
psimaging candidate
psbinding plasma
publisher guide
pvalues orr
raising debttype
raises possibility
randomized doubleblinded
randomized trials
range cancer
randomlength countertemp
raimund obers
quote httpwwwnasdaqcomsymbolpphm
qtr table
qfy gpmm
quality joins
quality programs
quote betterthose
quite extraordinary
provide basis
protocol httpwwwclinicaltrialsgovctshownct
product insert
product candidates
product approval
production highquality
profile which
program next
program aacr
producing redectane
prod system
primary tumor
primary responsibility
prior doxy
privacy policy
process operationalizing
process fcadcc
program ovarian
programs forward
prostate hellip
prostate cancer
protection hiv
protein advanced
protocol httpclinicaltrialsgovctshownct
protocol expanding
proposed pivotal
promising very
progressplans httptinyurlcomrhmlog
progressplans httptinyurlcomhnqa
proj httptinyurlcomyrwqm
project srbtradantips
promising new
promising lsquoimmunoindicativersquo
point itll
pneumonia lassa
patent granted
patent app
parttime emps
pathway bavituximab
patient pop
patient therapies
patient population
partners ibc
partnering discussionsrdquo
particular type
part important
parties continue
partner board
partnering activities
partnerdriven bavisorafenibliver
patients ndline
patients placebo
per david
people lead
per rrdoghttptinyurlcomhbwzkq
perc cell
peregrine confident
peregrine adds
pending httptinyurlcommrfnsb
pcalone loeschjco
patients randomized
patients prior
patients sites
patients trialhellip
payable utswdallas
paul lytles
parseghian dirrd
parasite immunology
other peregrine
other org
other global
other tissues
out pphmtoolong
out study
out primary
orrrdquo httptinyurlcomaqnyny
orr sandlere
options exercisable
optimistic about
options few
oralpres snm
orr more
orig nabtt
outer membraneshellip
outline thorpes
pancreatic phase
pancreatic cancer
pancreatic randomized
pantginis physicians
pantophlets summary
pantginis question
package bring
oxford fin
outnumber tumor
outlined look
outperf httpwwwjmpgcom
over new
own product
over tntchina
peregrine enable
peregrine fda
pick httptinyurlcomrxbps
phpt enrollment
phn httptinyurlcomrxqqtk
piece point
pijeffrey meyer
piper jaffray
pipeline completely
phil reports
phil marfuta
phb protocol
phb ndline
phb randomized
phd chief
phiii design
phdosimetry trial
piperjaffray comments
pivotal phase
platform really
plans httptinyurlcomfhyzxz
platform theres
platform wide
plytle cowenboston
platformhellip antibodies
planning underway
planning initiate
placebocontrolled phase
placebo more
plain language
plan complete
planning going
planned virus
phb bavidocerefractnsclc
phase trials
peregrines patent
peregrines clinical
peregrines antips
periods time
personally dont
pfizers crizotinibxalkori
pfizerferretti amgenhansen
peregrines activities
peregrine should
peregrine head
peregrine finds
peregrine launches
peregrine pays
peregrine pool
peregrine pharmaceutical
pfs data
pfsmos mosmos
pharmaceuticals join
pharmaceuticals affected
pharmas secret
phase approval
phase iib
phase bavi
pharmaceutical test
phage pharmas
pgm maxmm
pghttptinyurlcomagyhn helliproyalty
pgmhellip also
pgms hellipceo
pgncis after
pgn test
just phenomenal
kings min talk
steve kings min
qtly conf call
both bavi arms
think data extremely
survival opens door
call kingshangarnicklytle transcript
think makes really
goal ndline nsclc
ndline nsclc clinical
very comfortable proposing
were currently evaluating
majority patients still
approval point options
most efficient path
article immunopet imaging
case certainly think
steps bavi ndline
considered peregrine working
consider one consideration
cotarabrain success story
data continue trend
discussions around pathway
data ive seen
enrollment taking longer
pivotal phase iii
ceo steve kings
ceo steve king
peregrine mourns loss
peregrine pharmas secret
expected amended protocol
pgm given favorable
like many things
hard very actively
years after diag
weve seen imagine
fda approval its
ipgn peregrinersquos psimaging
few more illustrative
fevers httptinyurlcomdxpup tmttransformational
fever thorpe developing
fda httptinyurlcomlpacm these
fda were process
fhbavichemo pgncis after
fda essentially registrational
fhbaviopticalimaging translational oncology
firm httptinyurlcomhryyj bavituximab
focus remains init
fold higher radiation
forex lounge hot
ipgn fab end
findings still tested
fhc dev project
fighting cancer recurrence
filing httptinyurlcommutbungler explains
financial results after
favorable trrs pfs
fastest route product
expansion niaid grant
expect continue some
expectations hope excited
iss httptinyurlcomcuqry prhttptinyurlcomcosut
expand commercial supply
existing commercial supply
exceeded expectations very
excerpts httptinyurlcomwque hellipsk
exec info report
expedited meeting fda
experience drug would
facility upgrades resp
fact even though
falsely writes thestreet
investorshubcom inc about
extraordinary stroke luck
extraordinary let animals
exploit fact viruses
exposed apoptotic tumor
expression system tnt
favorable results could
formulation psbinding mab
garnick saw over
garnicks work genentech
genentechs jan marik
generally accepted chemo
garnick joined peregrine
garnick headreg qtlycc
fye license agreements
fyq thru fyq
garnick headreg nsclc
generate sales byr
generating lot would
goal get spa
intrigued about bavis
goal secure regional
going able come
goal bring partner
gives avid case
given bavi results
given close attention
investigation agency well
future sci meeting
future partner part
forward working ceo
fourth quarter fiscal
frontline lung cancer
frontline nsclc httptinyurlcomkuuf
investigatorsponsored studies enhance
investigatorsponsored trials init
exceeded expectations hope
forward fund letter
forward seeing addl
ftms table mos
full archive dukepphmchavicavd
fund peregrine pharmaceutical
investigator sponsored trials
future exus partnerdriven
fullyhuman mabs antips
fullyhuman ipgn ind
investigatorsponsored ist phiii
fully human they
investigators believe vaccine
forms antiviral research
exactly seen both
dose arm likely
dose arm were
dose ratio showing
dose response correlation
dose arm been
jeff hutchins presenting
division angiogenesis tumor
donald senger joins
dont believe question
doses prolonged periods
doubling mos mos
drthorpes min talk
drug candidates within
drug designation cotara
drug development commercial
drthorpe neoplasia article
dream through hellipdr
dovetails very beautifully
dozen leading research
dramatic potential market
distribution different mammalian
disorders cancer diabetes
difference pooled dataset
different potential targets
differentiating factors between
disclosed before sept
diff survival between
dev interferonfree treatments
designation updated numbers
desire compare cotara
desire explore different
discovery grant httptinyurlcomfunn
discuss same trial
jmpnyc httptinyurlcomcsdclwb hellipsk
disease well starting
diseases cotara ichtntb
jeffery kraws httptinyurlcomdjauo
disease very low
disease until they
discussed fda bavidoce
discussed qtly conf
discussion possible addl
drug highly partnerable
drug nsclc alone
enrolment complete httptinyurlcomcqrupe
entry point into
envelope protein advanced
eop meeting fda
its endless part
enrollment httptinyurlcomvqk helliphellipup
enrollment complete baviribahcv
enrollment complete httptinyurlcommre
enrollment complete httptinyurlcomvvzfx
esp mos trends
especially exciting administration
events httpirperegrineinccomeventscfm augndash
every type virus
evolution favored pathogenesis
issues been finalized
evaluating bavi treatment
evaluate panel new
establish pgm going
eur licensee merckkgaas
evade treatment would
its going very
its just matter
dukepphmhiv candidate pgn
janfeb buying streak
dukes bart haynes
duramycin little peptide
dukepphm hiv article
duke hiv collab
drugs httptinyurlcomcgnkvpa bull
drugs patients need
drugs potentially could
effects cancer treatment
efficacious clinical outcome
emps reside peregrine
encouraging results seen
enhances antitumor effects
eliciting hiv inhibitory
either bavi arms
efficacy joe said
effort fda trial
efforts new spinoff
going discuss entire
going other guy
httptinyurlcomyuxemu hellip thorpe
httptinyurlcomzqn ocbj pphm
httptinyurlcomzxqa disclaimer msg
httpwwwibclifesciencescomantibodyeng dec fyq
httptinyurlcomyulw other peregrine
httptinyurlcomyttt usa cotarabrain
httptinyurlcomyjmsod noteworthy since
httptinyurlcomykxznha hellipsk were
httptinyurlcomylbefh hellipsk resp
interim data showed
httpwwwmlvcocommlvcoverageuniversehtml lifetechcapsteve dunn
hutchins presenting pstargeting
hyclone bioreactors httptinyurlcomqgl
ibcs bioprocess intl
idctlihmainbodid classpageclr windowfbasyncinit
human antips antibodies
httpwwwpiperjaffraycomcolaspxid jmp securitiesjason
httpwwwnasdaqcomsymbolpphm pphm tweets
httpwwwnexavarcom protocol httpclinicaltrialsgovctshownct
httpwwwperegrineinccomtechnologyoverviewhtml peregrines bavi
httptinyurlcomyfdgsom hellipthe companies
httptinyurlcomybvu hellipsk next
httptinyurlcommk pending httptinyurlcomp
httptinyurlcommvzqn hellipthe abovefrom
httptinyurlcomndxtm sking ldquowe
httptinyurlcomnpnkp pending httptinyurlcommrfnsb
httptinyurlcommhrtld hellipsk were
interview baviav bmed
httptinyurlcomjtnano bull examples
httptinyurlcomkyas robert garnick
httptinyurlcommh bavi moa
httptinyurlcompjcbw prhttptinyurlcomkhpokw cash
interstitial catheter httptinyurlcomamxjw
httptinyurlcomwtgc see slide
httptinyurlcomxyd nasdaq last
httptinyurlcomyanfws hellipperegrines broadspectrum
httptinyurlcomyazk hellipdr thorpe
httptinyurlcomwrrso hellip ceo
httptinyurlcomudkgr antitumor activity
httptinyurlcomqhvx jill capps
httptinyurlcomqjxxh final data
httptinyurlcomresos bavi moa
ideal combination downstreamacting
ideally time eop
infections archive other
infections diseases hepatitis
infiltration breast cancer
info might otherwise
infection httptinyurlcomvluj sept
infected cells reducing
indias ctri registry
indication overall survival
indication specifically deliver
info peregrines clinical
info peregrines ist
interest bavituximab pgm
interest goal program
interest running clinical
interested curious still
intended confirm randomized
insight opened door
information regarding mechanism
innate adaptive immune
innovative monoclonal antibody
india study could
india expanded jan
immune checkpoint blockades
immune responses insideout
immune system fight
immunotherapy moa bavituximab
imaging trial using
imaging program aacr
ifu just click
ihub android app
iii pivotal trial
interhepatic bile duct
interesting target broadspectrum
including most dnas
including new combinations
increase ultimately survival
improvement mos bavimgmos
importantly past pphm
important issues remain
importantly cotara demonstrated
importantly mos ctlarm
httptinyurlcomhhln hellipatr differs
httptinyurlcomfjmpw hellipto develop
hellip peregrine launches
hellip peregrine provides
hellip peregrine receives
hellip phb trial
hellip enrollment complete
hellip chemistry world
heirapparent utsw longtime
hellip ascorsquofinal data
hellip ceo steve
hellip robert garnick
hellip sitc poster
hellipinterim mosmoswks eager
into one treatment
hellipon potential benefits
into more advanced
helliphellipweve been working
hellipdrthorpe these data
hellipcc jshan vpclinregaffairs
hellipceo sking goal
hellipdr shapiros cotara
heavily symptomatic started
healthcare conf scotsdale
great video semper
greater delivery radiation
grip tumor immune
group looking number
great utility technology
granted imaging antiviral
govt stockpile part
grant link httptinyurlcomntcm
grant utsws david
growing field represents
into phase iii
hcv cocktails httptinyurlcomnovgzk
hcvhiv coinfecteds mono
headclinscience httptinyurlcomyzfwyv hellipdr
healthcare conf nyc
design its going
happened many times
growthblocking mechanisms sorafenib
guide hepc treatment
guptas cns poster
helliprdquowith less than
helliprgarnick ldquothis highly
httpirperegrineinccomeventscfm sepavid booth
httpperegrinetrialscom bavi moa
httpstonsabiocom harry fanceostason
httptinyurlcomabmw ceo steve
httpclinicaltrialsgovshownct crpccastrationresistant prostate
httpclinicaltrialsgovshownct asco final
hopes bavi trial
however these specific
hsv keratitis see
httptinyurlcomagwno peregrines srb
httptinyurlcomamwyj elegere although
httptinyurlcomcnghzyv mlvgeorge zavoico
httptinyurlcomcycv expert quotescommentary
httptinyurlcomdmd avid bioservices
httptinyurlcomfgzg hellip wyeth
httptinyurlcomcaxap thorpemayo antips
httptinyurlcombwrat hellip peregrine
into humans antibodies
httptinyurlcomanmaa cotara holds
httptinyurlcomawg hellip new
homes specifically tumor
hivvaccine initiative httptinyurlcomxwjk
hellipvirus induced externalization
hellipwe believe optical
help faq site
hepc phase trials
hellipto execute cotara
hellipsteve king molecular
helliprobert garnick like
hellipsk based these
hellipsk escalate business
her mbc initiated
high dose arm
his firstever public
historical controls sufficient
hiv viral titers
hired meddir execute
highquality clinical documents
high unmet medical
highly efficacious producthellip
highly lethal ebola
interested parties they
days after each
avoid lengthy phase
bacteria infectionsdstl porton
barcelona httptinyurlcomklpodc hellipdr
barrowphoenix added formerly
avid producing redectane
avid presents new
avid becomes cmo
avid bioservices inc
avid bioservices remaining
avid expands capacity
based his basic
based tnt technologies
bavi correctly whereas
bavi doubled mos
bavi herpes semper
bavi imaging tumors
bavi acts upstream
bavi accelerated approval
basically take these
basically would animal
basis well support
avastinpcphn stage ivs
authorities its going
arms evidence discrepancies
arms would support
around potential bavituximab
arranges direct sale
arm were administered
arm peregrine expects
ari helenius philip
arius researchs lead
arm analysis indicates
arm currently demonstrates
article bavichemonsclc httptinyurlcomgzdg
article ccr baviarsenicimaging
atm fundraising httptinyurlcomdbsn
atr research httptinyurlcomybhl
attendee reports httptinyurlcombxfzu
auditorium guest web
astonishing amount progress
aspects genentechs business
article cleveland paper
article vaccine antips
ascending dose levels
bavi oncology program
bavi potential interferon
biologics demand references
biopharm httptinyurlcomxb stonsas
biopharmaceutical company developing
bioproduction contract affitech
binding correlated response
binding antihiv antibodies
bgpi binding they
bgpidepen genentech studying
bgpiindep dukepphmhiv candidateat
bhaynes targeting host
biosciences protease candidate
bioservices get very
blocks both vegfr
board recs shs
board type free
boards hot stockwiki
block spread several
blackrock inc larry
bioservices wholly owned
biosimilars services deal
biotechnology markets advance
bevacizumab approvals httptinyurlcomygvtqa
between cotara dosage
bavis pronged moa
bavituximab first new
bavituximab holds great
bavituximab may offer
bavis goal elim
bavirsquos supporting data
bavicp mosmos ldquowith
bavidoce ndline nsclc
bavips moa recombinantantibodies
bavituximab promising new
bavituximabs potential feel
before start phase
begins stmichaels peter
benzinga peregrine finds
bestcase result just
been administered monkeys
because huge unmet
bavituximabs potential ongoing
beasley interviews steve
because believe results
areas really think
area steve king
affiliated peregrine endorsement
affitech comments pgn
affitech press releases
affitechnts collab dev
advantages they bind
advancing program next
adequately address regulatory
administered low dose
advanced search videos
advancing program into
after primary tumor
against lassa fever
agent taking advantage
agents aacrccr article
aggressively pursue new
agreed good results
agent articles annual
agency inspections support
against numerous viruses
agencies promising survival
agency about accelerated
added univ lausanne
added selectikineradnsclc httptinyurlcompzlj
about bavituximabs potential
about much credibility
about ndline nsclc
about novel therapies
about accelerated approval
abbottmenender novartisevilevitch pfizerferretti
aacr brekken pphm
aacr pts todate
aacrncieortc confsanfran httptinyurlcomhpydn
about tarvacins antiviral
absolutely chock full
activities secure partnership
activity ticker buzz
activity vivo optimizing
adam yopp promising
active pace move
activate antiviral innate
absolutely nothing need
accelerated approval based
accelerated product approval
aims speed cancer
alan esptein usc
antitumor effects patients
antivegf mabs incl
antivegfc bull fullyhuman
antiviral agents treating
antipsvhfs preclin data
antipsvhf studies httptinyurlcomlxtuo
antips antiviral news
antips article httptinyurlcombsgvm
antips symposium nyc
antipsmoa sorafenibliver fhbaviimaging
antiviral factsheet pphm
apoptotic cells stress
approximate results weve
apr less than
april loui exgenentech
area high unmet
approved therapy nsclc
approval based those
app antilipid antibodies
applications pstargeting antibodies
appointed head medical
antiphospholipid syndrome cause
anticipating being commercial
also see httptinyurlcomlxpb
amdcnv arvoftlaud httptinyurlcomqkuwa
analysis results about
andrew sloan case
also just build
also great news
alliance network httptinyurlcomlnfn
also avid gets
also avid stgmpmfg
animal rule which
annual meeting httptinyurlcomlmhkw
antibody enormous potential
antibody homes tumor
antibody including treatment
antibody portfolios its
antibodies like bavituximab
antibodies demonstrated significant
annual mtgboston httptinyurlcommxzbzm
another ftm pancreatic
antibodies being assessed
boards site stats
body research points
conjugated antipsma vta
consistent safety profile
consultation regarding cotara
continue some period
conjecture most outlandish
confident enough data
conf call kinglytleshaneso
conf call kingshangarnickmastenesolytle
confer tumorspecific immunity
conference capetown soafrica
continuing ongoing partnering
contract mfg services
cotara pgms hellipceo
cotara phase iii
cotaragbm phdosimetry trial
cotaragbm singleinfustion dual
cotara clinical trials
cosegregate normally inside
contractpharma article subs
control arm comparing
corporate courage conduct
conf call kinggarnickshanlytle
conducted date under
company fortunate someone
company stonsa biopharm
companyinitiated trials hellipdr
companys pstargeting platform
comp coming weeks
commodities etf center
combinations look forward
comfortable proposing eop
commercializing tnt technologies
compared favorably avastin
compared other organs
compound investigators either
compound would take
comptrials nsclc nsclc
concepts into clinicrdquo
components adaptive immune
compliance httptinyurlcomykuw current
completed another order
completely phospholipids they
completely unencumbered look
cotaragbm trials history
cotaras targeting capabilities
data update ndline
data very very
data which were
david miller idea
data set believe
data results could
data gend singlearm
data ibcconf httptinyurlcomypd
data immune stimulating
data provide basis
job adsrmedwriter httptinyurlcombtdbae
dcgi protocol init
delivery pub neurosurgery
demand httptinyurlcomchuyo hellipest
demographics baselines treated
depending particular type
define optimal registration
dec nature medicine
deal httptinyurlcomkrxk full
deals should add
dec annual piper
data error httptinyurlcompucqn
data cutoff bavi
courage conduct rigorous
cprit award antips
cprit award thorpeetal
cprit grants philip
couple weeks most
could support moving
could become biggest
could lead future
could sufficient support
csa addl partnered
csa rhuph signed
cutoff httptinyurlcomysfed short
dampen enthusiasm bavituximab
data china httptinyurlcomggcba
data combined human
currenty halted stocks
currently planning going
csm breach contract
ctlbavi mos mos
curr outperf httpwwwjmpgcom
combination full results
collaboration httptinyurlcompjqt iii
cancer httptinyurlcomgazv supg
cancer httptinyurlcompobktc helliprdquoa
cancer initiated utsw
cancer trial initiated
cancer hellipyour expertise
cancer clinical results
call kingesolytle transcript
call kinggarnickshanesolytle transcript
cancer also very
cancer challenges asian
cancer trials above
cancer trials archived
candidates such subcutaneous
capetown aids commenting
car liked justmarried
carlton johnson appointed
cancers phase trials
cancers other diseases
cancer typerdquo bull
cancerfighting immune responses
cancers involving brain
call httptinyurlcomphqr hellipdr
buy cheaper sharesbut
brain lung pancreatic
brazilian collabs inca
breast cancer openlabel
breastcancer conf httptinyurlcomutya
brain cancer therapy
brain cancer peregrine
boehringer ingelheims global
boston httptinyurlcomlpew hellipaug
both lipids flip
brekken pphm srb
bring significant monies
build really platform
bull fullyhuman bavipgnn
bull pgn human
burzynski movie sequel
bronchs prostate hellip
brokers educational channel
broad aminophospholipidtargeting platform
broad potential treatment
broad spectrum antiviral
cash position httptinyurlcompmcgsgp
cbdst biodef conforlando
clinical potential exciting
clinical sites goal
clinical study gbm
clinical trials cotaras
clinical oncology setting
clinical imaging pgm
clade hiv isolates
class antips therapeutics
class historyhellip believe
clearance rates halflife
clinical trials link
clinical trials welcome
collab article jem
collaborate clinical researchers
collaborating catalyst dev
collaboration dukes bhaynes
coliganrsquos phd chief
cmv rsv arenavirus
clotting disorders one
cmo avid bioservices
cmo subsidiary which
cjgaddy entdoc keeptrying
chris reutlingsperger david
certain apec countries
certainly before beg
cfo paul lytle
cfo paul lytles
ceo sking refer
cells creates vast
ccr aacr article
cell biology section
cells attack tumor
cfo plytle cowenboston
chance some cancer
chi confboston httptinyurlcomoboq
china lung cancer
china shanghai medipharm
chirsquos ldquothe immunotherapies
checkpoint thus makes
checkpoint inhibitors such
changed partnering discussions
charts mos data
chasingthealpha chimera research
design gbm httptinyurlcombjowgh
kda they slower
srb ldquoclipped bgprdquo
srdir quality joins
stands just over
starting phiii trial
spectrum antiviral agent
specifically target tumors
sorely missed colleague
spa fda conduct
space avid exp
sparked surge partnering
stated goal partner
stated goal pursue
steve king considers
steve king jmpconfnyc
steve king qtlycc
steve king strength
step next decade
std really counts
statistical significance efficacy
status cotara phase
status true cookie
some low dose
some combinationtherapy potential
shown promise study
shows immunosuppressive effects
signs biosimilars services
simplifying transition experimental
showed pstargeting antibodies
show broad therapeutic
shareholders werent told
shiv spp studies
shorter patrick crutcher
should recognized having
since reactivation immune
since time major
small molecule quite
smi thorpemason optical
soc temodar gbm
solid cancers usa
slowenroll new soc
sks slideshow capture
siro clinpharm peregrines
sites goal fullyenroll
sites httptinyurlcomwcr orig
steve king these
still patients treatments
supreme courts decision
surfaces inhibit hiv
survival advanced preclinical
survival advantage substantial
suppression leishmania infection
support moving forward
sui shen ualabama
suit filed against
supervising investigatorsponsored trials
supplies management inc
survival events while
survival number patients
talk roth stock
targeted approacheshellip preclinical
targeting nanoparticles which
team utsw hamon
talk needham healthcare
take advantage potentially
survive avg thats
symposium title phosphatidylserine
system might manipulated
suggett exgenentech srproductdirregulatory
sufficient marketing approval
strategy advance novel
strategy bavi clearly
strategy intriguing concept
strength ndline nsclc
stonsa biopharm pubs
stock screener news
still significant unrealized
stline nsclc ctlcp
stock chart httpstockchartscomhscuispphm
stride again interview
studies httptinyurlcomlxtuo inventor
such lsquobetabodiesrsquo potentially
such rituxan herceptin
sues csm over
sufficient capital fund
such large multinational
sub ibc bioproc
studies side effects
study drug various
study significant because
shans min webcast
several months less
recently filed ind
recurrences also contrasts
referring registrational trial
refractory disease which
received approval fda
recaps ndlinensclc data
reached mos ctlarmdoce
reads orr pfsmos
real interesting part
really easier approach
regclin strategy httptinyurlcomavred
registration pathway cotara
remain halozymes cmos
remarkable result since
remarkable results only
remarkable results statistically
rely clinical data
relevance new therapeutic
registrational protocol httpclinicaltrialsgovctshownct
regulatory people kathryn
relations data accreditations
rdquothis thorpersquos vta
rates raising debttype
qualities antibody terms
quality images quite
quality programs facilitate
quote betterthose forget
pvalues orr stats
public comments thru
pstargeting clinical imaging
pstargeting preclin data
pstargeting presentations httptinyurlcompzs
pts designed assess
rabbit model acute
raises possibility pgn
range viral infectionshellip
rapid approval process
rare disease space
rat antivegf mab
randomized trial initiated
randomized reg trial
randomized doubleblinded placeboctld
randomized openlabel protocol
randomized placebocontrolled phase
removed critical line
repeatdose hcv trial
rrnyc httptinyurlcomfagxw hellipsking
russiacis httptinyurlcomhezkux hellipaffitech
russian partner ntsplus
said also exp
rothocdanapt httptinyurlcomqym hellipsk
roth raises pphm
robert garnick httptinyurlcomlgoras
rodmanren jaikariabenjamin initiate
rolf brekkens research
roth adds pphm
sales futureapproved antips
schroits patents mda
see most remarkably
seek accelerated approval
seen really very
selling monoclonal antibody
see httptinyurlcompjovt bull
securities life sciences
sdstabledisease red incr
secured mmimmed mmoption
securities healthcare confnyc
rob garnick extended
road think theres
resulted more than
results new control
results out study
results really want
responses httptinyurlcomcwodb bavi
research funding evaluate
reporting data later
represents potentially valuable
represents unique opportunity
reutelingsperger philip thorpe
reverse tumorinduced immune
right following discussions
right which feel
rim also continue
ringmaster king says
revs recdmm httptinyurlcomphqr
reviews article cotaragmb
review able generate
review httptinyurlcomansqcea hellip
review upd httptinyurlcombfjmva
technologies tmt wwwtmticbdefenseorg
test bavi herpes
very disturbing biopharm
very few far
very near future
very positive mos
very conservative approach
vegfrgel lic pphm
vaccines after step
valuable new approach
value company partners
vegfrgel expected open
very promising very
vessel marker which
videos investor help
view posters pphm
viral infections its
viral infections using
video presentation late
via targarosenblum httptinyurlcomylevod
vessels beautifully tumors
vessels induces white
vhf whats interesting
vaccine mice antibodyil
utswdr rolf brekken
upd twice month
updated clinical trial
updates bavituximab pgm
ups neutral buy
unmet medical need
unique potential indication
underway already goal
unified trial accomplish
uninfected cells vitro
unique mechanism action
usa cotara brain
usachina firm httptinyurlcomhryyj
using pgnfhubavi potential
using zrpgn seegenentech
utsw mda ucalif
utsw pijeffrey meyer
using pgn inhibit
uses invention suitable
used cotara gbm
used discussions fda
used drug ndline
viral membrane envelope
visibility should represent
which only blocks
while peregrine httptinyurlcompeqxrt
whos registry httptinyurlcomkcpz
whose ind clinical
which natural tiein
which means eop
wgtavg exercise price
which bavi vhf
which going double
which important efficacy
wilexiba germanybelgium httptinyurlcomkre
william shapiro barrow
would look experience
would obviously talk
wwwdtramil fpdsgov httptinyurlcomjbmkcg
yearend fiscal year
would ideal partner
would been completely
work together evaluate
work whole goal
world imaging congresssdiego
weve been working
weve been raising
vta dev programs
wait those results
water systems upgrades
wave medicines tap
vspconly httptinyurlcommrya helliplocal
vpquality httptinyurlcomqxuvso exciting
visit peregrinetrialscom clinicaltrialsgov
vivatuxin lung cancer
vladimir evilevitch exparexel
well potential partners
well underway explore
were very confident
were very eager
werent able achieve
weve already begun
were point were
were intrigued see
were alan schroit
were doing something
were expecting show
ucker ari helenius
twitter ihub iphoneipad
thrombosis research article
thrombus issues httptinyurlcomddqh
through numerous phase
thru capital markets
those both funding
thorpes poster pgn
thorpe coauthor jclininvestigation
thorpe determining role
thorpe whole new
thorpes articles httptinyurlcomcsjsl
time duramycin binds
time publicly most
today both bavi
today httptinyurlcomkvplmj detail
today still reached
together lack apparent
today article pphms
tntchina website httpwwwvivatuxincom
tissues thats just
tmoodys talk incl
tmtdtra extend vhf
thirdparty vendorhttptinyurlcomrzcqy hellipinvestors
thirdparty clients prepare
themselves outer membrane
therapeutics labs ctl
therapy against choroidal
therapy gbm patients
thats well take
thats absolutely unbelievable
texas cprit httptinyurlcomcsmk
than mos doce
than natural antibodies
therapy play major
therapy well ultimately
things come those
things could much
think excellent opportunity
think tremendous potential
thing fact even
theyre beginning outnumber
these ists very
they agree robert
they suggest new
toolong without partners
tools charts trader
trial preferably before
trial protocol added
trial protocol init
trial provided these
trial peregrine confident
trial patients ndline
trial mixup httptinyurlcomfpgngu
trial most thrilling
trial ndline nsclc
trial partnering phase
trial update httptinyurlcomcoq
trial which showed
tumor necrosis therapy
tumor response therapy
tumor than normal
tumors httptinyurlcomcwodb hellip
tumor imaging agent
tumor growth without
trials archived httptinyurlcomffc
trials table showing
trying give hard
trial ipgn fhbavi
trial initiated httptinyurlcomuztv
transcript httptinyurlcomkhpokw ceo
treat patient pop
treated tumor models
treating brain cancer
transcript httptinyurlcomkassc hellipsking
trans novas buyout
top boards most
towards eop meeting
trades portfolio top
treatment complete cotaragmb
trends large area
trial hellip topline
trial httptinyurlcomwrq hellipjshan
trial init comp
trial initiated httptinyurlcomkxksl
trial enrollment complete
trial design weve
trial after data
trial asia httptinyurlcomlatcq
trial design bavi
pstargeting antibody platformhellip
prrussel rebalance mrpatinmn
near approaching saw
near term completed
need also sparked
need new treatments
ndline nsclc phb
ndash see httptinyurlcomnqqkm
nabtt cotaragbm patient
name bavituximab avoid
nature medicine article
ndash see httptinyurlcomkhopad
negligenceserved httptinyurlcomazrgys hellip
nervous systems breast
new development opportunity
new fda breakthrough
new found lifehttptinyurlcomatlb
new irs therapeutic
new combinations previously
new clinical protocol
new approach imaging
new bavinsclc study
new cancer vaccine
multmilestones asm webcast
msg follow board
mos ctlarmcombined bavimg
mos either bavituximab
mos gemmos gemtrmos
mos improvement topshttptinyurlcommctb
mos bavituximabcontaining arms
moredifficult squamous bavi
more detailed results
more ihub facebook
more importantly findings
more motivated than
mos only great
mos pcalone loeschjco
moving ahead simple
moving bavi into
moving fwd addl
mrpyou saidi thousands
most posted most
most importantly past
mos reported asco
mos result its
mosmos mos docealone
new principle virology
new scientist article
oct annual shareholders
oligodendroglioma which carries
oncology discussions ongoing
one potential anywhere
observed thorpes augjan
objective newly funded
nsclc patients trialhellip
nsclc personally dont
nsclc trials bavis
number wayshellip more
ongoing addl parties
ongoing bavidoce randomized
orr more than
orr pfsmos mosmos
orrher pfsmos mosmos
osis anticancer drug
options few rarely
opportunities everything immunocytokines
ongoing potential partners
openlabel note sorafenib
openlabel phbiia cancelled
nsclc patients receiving
nsclc patient population
news see httpperegrinetrialscom
niaid ldquoparticularly interested
nih awards abl
nihniaid grant research
news see above
news peregrine pharmaceuticals
news alerts commodities
news certainly disappointing
news httptinyurlcomvmkzm hellip
nmb article bavi
nor been actively
novndash credit suisse
nsclc clinical trial
nsclc data esp
nsclc openlabel phb
novel monoclonal antibody
novel cuttingedge pharmaceutical
nor pfs really
nothing else like
novdec affitech reiterates
moody antilipidspgn talk
modification everything hear
like point out
like see diagnostic
lipids insideout drugs
list top biotech
lifetech downgrades pphm
licensing opportunities httptinyurlcomerhh
ldquothis new bavi
lead ind phase
licensee httptinyurlcomzcjqr clearly
licensing agreement httptinyurlcomcnc
little staining seen
live charts live
long history fda
long these patients
longer serum halflife
looking ability describe
load them different
lnsclc trial most
live desktop forex
liver cancer hcc
lloyd dunla drug
ldquopotentially next generation
launch peregrines products
july peregrine public
just described feel
justify moving bavi
yrs httptinyurlcommhboa previous
jrnlchromatography httptinyurlcommcw hellip
joins pphm meddirector
joe pantginis physicians
join peregrine bavituximab
joins peregrine directorqa
joins peregrine head
keep those potential
kenneth dart eastern
kingshanlytle transcript httptinyurlcomrfwrv
labeled imaging tracers
labs abl httptinyurlcomgsshelhhsni
language httptinyurlcommftnd shares
kingshangarnicklytle transcript httptinyurlcomnkwrml
kinggarnickshanlytle transcript httptinyurlcombxeat
key regulation immune
keynoter recombinantmabsbarcelona httptinyurlcomklpodc
king head regulatory
looking nice bounce
looking very seriously
methods treating viruses
mfg subsidiary httpwwwavidbiocom
mgkg arm continues
mgkg armhellip peregrine
merckkgaas selectikine nhsilltemd
merck kgaagermany pidr
medsurvival beyond mos
meeting communicated interested
meeting fda would
members recent news
mice even administered
michael kurilla mention
mmeuro ibc pphm
mmimmed mmoption oxford
moapotential httptinyurlcomnmdw peregrines
moderator moderator ezlibra
min talk onemedforum
min talk nyas
mid topline data
milestone pphm preclinpkg
min talk bioceo
medarex httptinyurlcomdvrt these
mechetner formed which
lowdose arms comparator
mab demonstrated broadspectrum
mab pgn fhbavi
mabs acted host
low single digits
lot those out
lot effort lot
lot interested parties
lot into orr
mabs stimulate cancerfighting
major accomplishment knock
many new development
matter magnitude weve
may better side
measure which mos
malignancies aacr tumor
making antiviral drugs
major players oncology
major solid tumor
make judgment top
other biomarkers evaluated
other fundraising activities
potential illustrating exposed
potential ist indications
potential marker imaging
potential ndgen treatments
potential feel strongly
potency wholecell breast
poster aacr httptinyurlcombmlpx
posters arvo annual
posters pphm poststream
posting pphm review
potential other pstargeting
potential partner initiate
potentially providing unique
potentially used engage
pphm add pphm
pphm detailed quote
potentially other global
potential triggers conclude
potential regulatory pathway
potential targets therapeutics
potential targets therapy
posted pphms homepage
possibility making diagnostic
plasma membrane activated
plasma protein bglycoprotein
platform infectious diseases
platform theres actually
planned virus therapy
planned created lot
placebocontrolledhellip goal being
plan complete evaluation
plan eur agency
plan pivotal phase
play guessing game
plenary astrothoracicchicago httptinyurlcomwrrso
points randomized trials
poison pill adopted
polyreactive antips antibodies
pool results placebo
point out many
point end april
plos pphmbrekkenutswaffitech article
plos rbrekken pphm
pneumonia lassa fever
pphm director regulatory
pphm files shelf
program ovarian cancer
program position ourselves
proj pgm maxmm
project srbtradantips httptinyurlcomclhzbx
profile todate httptinyurlcomyrwqm
profile shanghai medipharm
product could acquired
product effectively into
product insert lists
profile pphm board
promise prevent lung
promising treatments millions
protocol httpclinicaltrialsgovctshownct hellip
protocol httpwwwclinicaltrialsgovctshownct note
protocols ocular applications
provided these robust
protocol assessment approved
protein agil httptinyurlcomoaqp
prophylactic innovations number
proposed pivotal trial
prostate initiated uci
process fcadcc client
prior study could
pphmstason collab tnt
preclin dev hiv
predictive response evaluating
prepare revolutionize patient
pphms apts antipsg
pphmduke jem article
pphm httptinyurlcomdjw pphms
pphm licenses tnt
pphm news correction
present antips data
present its case
presents stifel nicolaus
presents tnt taiwanese
previous posts internetforumuser
primary responsibility establishing
presents antipsvhfs preclin
presented antiangio symposium
presentation understanding tarvacin
presentations other documents
presented aacr pancreatic
pittsburg piliza villaruz
piper jaffraycharles duncan
path being outlined
patient dosed indian
patient response range
patients placebo arm
patent granted expands
past predict future
partnering deals which
partnering discussions included
partnering meetings since
partners antiviral pgm
patients previously untreated
patients randomized into
pegs httptinyurlcomonj affitechpphm
people lead justmarried
perc cell line
peregrine also operates
pdf httptinyurlcombsp asco
pcalone httptinyurlcomphtty comp
patients secondline nsclc
patients trialhellip hellip
patientshellip planning initiate
partnering activities continuing
partner board participate
outline thorpes role
over bavi phb
over new combined
over tntchina licensing
outer membraneshellip raised
outcome reviewhellip rob
other immunotherapeutic agentshellip
ourselves along potential
out strategy financing
own advice internetforumuser
own product pipeline
part reducing harsh
participate eop meeting
particular interest liver
parties showing interest
part overall clinical
parseghian dirrd presents
package bring innovative
pancreatic randomized unblinded
parasitic disease httptinyurlcomju
peregrine avid drive
peregrine enable them
phase iii trial
phb bavidocerefractnsclc could
phb data presented
phb ndline nsclc
phase iii registration
phase iib registrational
pharmaceuticals nasdaq pphm
pharmaceuticals provides update
phase approval approach
phase bavimono singledose
phii lnsclc httptinyurlcommyqxw
phiii design lnsclc
phils dream bringing
phpt enrollment completed
pipeline assets chart
pipeline includes bavituximab
philip thorpe utsw
philip thorpe biopharm
phil marfuta bannister
phil reports yasg
phil thorpe eward
phage pharmas bacteriophage
pgn test data
peregrine pharmaceuticals inc
peregrine pharmaceuticals join
peregrine provides update
peregrine report fourth
peregrine other org
peregrine must determine
peregrine fda been
peregrine its collaborators
peregrine launches pstargeting
peregrine should recognized
peregrines activities glioblastoma
pgm well expanding
pgmhellip also great
pgn bgpidep fullyhuman
pgn presented aacr
pgm potentially providing
pfizers crizotinibxalkori fact
peregrines antips mabs
peregrines mfg subsidiary
pet imaging radioisotope
job vacancynet mrpatinmn